Immediate zoledronic acid treatment better than delayed in women receiving letrozole
the ONA take:
Immediate treatment with zoledronic acid prevented bone loss compared with delayed treatment in postmenopausal women receiving letrozole for breast cancer and these differences were maintained at 5 years, a study published in the American Cancer Society journal Cancer has found.
Because it is known that postmenopausal women with breast cancer receiving aromatase inhibitors are at a higher risk for bone loss, researchers sought to compare the impact of immediate versus delayed treatment with zoledronic acid on bone loss.
Researchers analyzed data from 551 postmenopausal women who had received tamoxifen and were now receiving daily letrozole. Patients were randomly assigned 1:1 to upfront or delayed zoledronic acid 4mg IV every 6 months.
Results showed that the incidence of a 5% decrease in the total lumbar spine bone density was 10.2% and 41.2% in the upfront and delayed groups, respectively (P < 0.0001), suggesting that immediate treatment prevented bone loss moreso than delayed treatment at 5 years; however, researchers found that the incidence of osteoporosis or fractures was not significantly different between treatment arms.
Immediate treatment with zoledronic acid prevented bone loss compared with delayed treatment in breast cancer.
Sign Up for Free e-newsletters
- Leukemia Risk in Children, Maternal Use of Hormonal Contraception Linked in Population Study
- CheckMate 067 Gives Nivolumab Alone, With Ipilimumab the Nod in Advanced Melanoma
- New Method Estimates Risk for Breast Cancer Recurrence
- Molecular Features May Predict Response in Primary Pancreatic Cancer
- Medication, Vaccination Uptake Improved by Involving Pharmacists in Elder Cancer Care
- Navigating Prostate Cancer: A Patient's Experience From Diagnosis to Survivor
- Cell Phones and Cancer Risk (Fact Sheet)
- How Likely Are Oncologists to Refer for Palliative Care? Depends on Their Age
- Use of Corticosteroids With PD-1 or PD-L1 Inhibitors Associated With Poorer Outcomes in NSCLC
- Chemoimmunotherapy Increases Survival in Triple-Negative Breast Cancer
- Counseling Patients on Oral Chemotherapy
- Patients and Caregivers Worry About Cost of Cancer Care
- Stem Cell Transplantation Superior to Chemotherapy for Relapsed/Refractory DLBCL, Follicular Lymphoma
- Head and Neck Cancer Survivors Have Increased Suicide Risk
- Hodgkin Lymphoma Survivorship Marked by Periods of Actionable Distress
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|